Oral Antidiabetic Drugs Market, By Drug Class (Biguanides, Thiazolidinediones, Dipeptidyl Peptidase

Published Date: | Report Code : HC2068385


Oral Antidiabetic Drugs Market, By Drug Class (Biguanides, Thiazolidinediones, Dipeptidyl Peptidase IV Inhibitors, α-Glucosidase Inhibitors, Insulin Secretagogues, Amylin Analog, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Others), By Region (North America, Europe, Asia Pacific, Middle East & Africa, and South America) – Market Size & Forecasting To 2028

COVID-19 Impact : Our team has been closely monitoring the current developments to identify the potential impact of COVID-19 on stakeholders and business processes across the value chain of industries. A special section about COVID-19 will be covered with the report to help companies in defining sustainable strategies.

Domain : Healthcare

Report Code : HC2068385

Status : Upcoming

The Oral Antidiabetic Drugs Market report points out national and global business prospects and competitive conditions for Oral antidiabetic drugs. Market size estimation and forecasts were given based on a detailed research methodology tailored to the conditions of the demand for Oral antidiabetic drugs. The Oral antidiabetic drugs market has been segmented by drug class (biguanides, thiazolidinediones, dipeptidyl peptidase iv inhibitors, α-glucosidase inhibitors, insulin secretagogues, amylin analog,  sodium-glucose cotransporter-2 (sglt2) inhibitors, glucagon-like peptide-1 receptor agonists, others). Historical background for the demand of Oral antidiabetic drugs has been studied according to organic and inorganic innovations in order to provide accurate estimates of the market size. Primary factors influencing the growth of the demand Oral antidiabetic drugs have also been established with potential gravity. Major regions covered in the study include North America, Europe, Asia Pacific, Middle East & Africa, and South America.

Market Segmentation:

By Drug Class:   

  • Biguanides
  • Thiazolidinediones
  • Dipeptidyl Peptidase IV Inhibitors
  • α-Glucosidase Inhibitors
  • Insulin Secretagogues
  • Amylin Analog
  • Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
  • Glucagon-Like Peptide-1 Receptor Agonists
  • Others

By Region:

North America Oral Antidiabetic Drugs Market

  • North America, by Country
    • US
    • Canada
    • Mexico
  • North America, by Drug Class

Europe Oral Antidiabetic Drugs Market

  • Europe, by Country
    • Germany
    • Russia
    • UK
    • France
    • Italy
    • Spain
    • The Netherlands
    • Rest of Europe 
  • Europe, by Drug Class

Asia Pacific Oral Antidiabetic Drugs Market

  • Asia Pacific, by Country
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Indonesia
    • Rest of Asia Pacific 
  • Asia Pacific, by Drug Class

Middle East & Africa Oral Antidiabetic Drugs Market

  • Middle East & Africa, by Country 
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of Middle East & Africa
  • Middle East & Africa, by Drug Class

South America Oral Antidiabetic Drugs Market

  • South America, by Country 
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • South America, by Drug Class

Major Companies: Novartis AG, Eli Lilly and Company, Merck & Co., Inc, Novo Nordisk A/S, Johnson & Johnson Services, Inc., Teva Pharmaceuticals Pvt Ltd., F. Hoffmann-La Roche Ltd., Sanofi

Years Covered in the Study:

Historic Year: 2017-2018

Base Year: 2019

Estimated Year: 2020

Forecast Year: 2028

Objectives of this report:

  • To estimate market size for Oral antidiabetic drugs market on regional and global basis.
  • To identify major segments in Oral antidiabetic drugs market and evaluate their market shares and demand.
  • To provide a competitive scenario for the Oral antidiabetic drugs market with major developments observed by key companies in the historic years.
  • To evaluate key factors governing the dynamics of Oral antidiabetic drugs market with their potential gravity during the forecast period.

Reasons to Buy This Report:

  • Provides niche insights for decision about every possible segment helping in strategic decision making process.
  • Market size estimation of the Oral antidiabetic drugs market on a regional and global basis.
  • A unique research design for market size estimation and forecast.
  • Identification of major companies operating in the market with related developments
  • Exhaustive scope to cover all the possible segments helping every stakeholder in the Oral antidiabetic drugs market.


This study is customized to meet your specific requirements:

  • By Segment
  • By Sub-segment
  • By Region/Country
  • Product Specific Competitive Analysis

For more information, contact: [email protected]

License Offering

Single User (PDF)


Multi User (PDF)


Enterprise User (PDF)


Get Regional Report @ USD 2000 Only

Your personal details are secure. Privacy Policy

Buy Chapters of Sections

Avail customized purchase options to meet your exact research needs.

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities
Detailed Coverage

Detailed scope covering all the major segments in the market

Meticulous Data Validations

In line data validations to ensure data precision


Market recommendations supporting decision making processes

Analyst Support

Round the clock analyst support to resolve your queries

Free Customization

Up to 15% additional free customization to meet your specific requirements

15% Free Customization

Share your Requirements

Questions?  Speak to an Analyst

Your personal details are secure. Privacy Policy